Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma.

Niloufer Khan,Farhad Khimani,Andrei R. Shustov,Mazyar Shadman,Jia Ruan,Alison J. Moskowitz,David J. Straus,Anita Kumar,Craig S. Sauter,Andrew D. Zelenetz,Ariela Noy,Gunjan L. Shah,Matthew J. Matasar,Pamela Drullinsky,Audrey Hamilton,Esther Drill,Koen van Besien,Sergio Giralt,Steven M. Horwitz,Parastoo B. Dahi

Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma.

2021

7533Background: Peripheral T-cell lymphomas (PTCL) have suboptimal outcomes with conventional chemotherapy. Autologous hematopoietic stem cell transplant (AHCT) is a therapeutic strategy for patien...

Keywords:

conventional chemotherapy
Internal medicine
therapeutic strategy
Medicine
Hematopoietic stem cell
T-cell lymphoma
Oncology
Stem cell
Romidepsin
high dose chemotherapy
multicenter study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations